 So this workshop is arranged within the framework links, where is a team called Integrative Pharmacology and Drug Discovery, which many of you have heard about before. This one is actually not working. And in that theme, we're working on structured-based drug design going from small molecules, macro molecular drugs into play with tissue. Let's see if we... Nope. Which is it on? I would say it's really just a little... Okay, so maybe if I... So here is the core group. You've seen myself previously, and this core group is led by Colin Lee, please, I don't know if it's calling him. No. And then there are a number of distinguished members in that group, Ramita, Anna, Sander, he's rather than them, we can't don't scan. Nope. So in the theme there are three working groups and we are representing today the third working group. But I just wanna mention that there are two other working group. This third group is about biomedical imaging. And the other two is about structured-based design led by Ramita and the macro molecular drug drugs and antibodies led by Anna. And the other groups have other activities that you might be interested in and you can find them at links of course. Was it me now or you? Right. Okay. So the mission of the working group is this working group three is to provide an arena for scientists to meet around biomedical imaging to drug discovery and development. And the purpose is to create an arena where scientists from both the academia and industry can gather and learn about cyclotron imaging, the ones who need that learn about drug development, persons who need to learn about that get them all together to benefit the drug development process in the framework of cyclotron imaging. Just a little bit about the schedule for our working group. We are here now in 2022. It says the webinar, but luckily we have a combined webinar and active workshop. So that it's better. We did this present, this outline when we didn't know really how the pandemic would evolve. So next event, which is scheduled for a workshop in early 2023 will be postponed because we have this workshop now. And the members, you have met already Oksana here who introduced the workshop. What we have members from all over Europe I would say some of them are in the room. There are medical doctors, Kareem Panoon, Mark and Isabel Gonzales and Zambaya from Grenoble and there's Matt Lundbeck who's going to speak later here from Lund, he was here there for the last 15 years. He's the upcoming speaker here from AstraZeneca on the inside zone. Also from Lund, Emmanuel Larson from Lynx and Microsoft. Kareem and Mokso is somewhere here in the room, yeah, there. And Anja Schmidt was also here with that, yeah. And then we have a great help from Anna and Nina in the Lynx. So what we're going to talk about today is really how imaging can help write development. And this is just a graph of how many, many candidates on your left-hand side go down to one which will end to a new drug application. And as you might know, synchrotron imaging is already used in the beginning of the drug development process, the drug discovery and the imaging as such is used later on and I'm sure that they could talk about that and how that is done. So the program we already said that's we don't have to repeat by that. I think we are ready for the first speaker.